BioGaia AB

BIOG B

SE0017769995

Pharmaceuticals

Market Closed - Nasdaq Stockholm Other stock markets 11:29:44 2024-05-17 am EDT			5-day change	1st Jan Change
130.9 ^SEK	-1.06%		+4.89%	+29.35%

May. 07	Nordic Shares Closed Up Tuesday; Storskogen Group Series B Topped Leaders	DJ
May. 07	Transcript : BioGaia AB, Q1 2024 Earnings Call, May 07, 2024

Biogaia AB Provides Earnings Guidance for the Second Quarter of 2022

July 14, 2022 at 02:00 am EDT

BioGaia AB (publ) provided earnings guidance for the second quarter of 2022. For the period, Sales are preliminarily estimated at SEK 288 million (203), up 42% and Operating profit is preliminarily estimated at SEK 101 million (69), up 46%.

Latest news about BioGaia AB

Nordic Shares Closed Up Tuesday; Storskogen Group Series B Topped Leaders	May. 07	DJ
Transcript : BioGaia AB, Q1 2024 Earnings Call, May 07, 2024	May. 07
BioGaia AB Reports Earnings Results for the First Quarter Ended March 31, 2024	May. 07	CI
Nordic Shares Rose Wednesday; BW LPG Led Increases	Apr. 03	DJ
Nordic Shares Decreased Thursday; BioGaia Series B Posted Biggest Loss	Mar. 28	DJ
Nordic Stocks Moved Upward Wednesday; Nordic Semiconductor Climbed Highest	Feb. 07	DJ
BioGaia AB to Seeks Acquisitions	Feb. 07	CI
Transcript : BioGaia AB, Q4 2023 Earnings Call, Feb 07, 2024	Feb. 07
BioGaia AB Reports Earnings Results for the Fourth Quarter and Full Year Ended December 31, 2023	Feb. 07	CI
BioGaia AB Proposes an Extra Dividend, Payable on May 15, 2024	Feb. 07	CI
Biogaia AB Proposes Ordinary Dividend, Payable on May 15, 2024	Feb. 07	CI
Transcript : BioGaia AB, Q3 2023 Earnings Call, Oct 20, 2023	23-10-20
BioGaia AB Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	23-10-20	CI
BioGaia AB Announces Nomination Committee for the 2024 Annual General Meeting	23-10-18	CI
Biogaia AB Provides Preliminarily Earnings Guidance for Third Quarter 2023	23-10-16	CI
Biogaia AB Appoints Theresa Agnew as CEO	23-09-25	CI
BioGaia AB Introduces BioGaia Prodentis KIDS in Sweden	23-09-01	CI
BioGaia Names New CEO	23-08-02	MT
BioGaia Appoints Theresa Agnew as New CEO, Effective September 25, 2023	23-08-02	CI
Transcript : BioGaia AB, Q2 2023 Earnings Call, Jul 21, 2023	23-07-21
BioGaia AB Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023	23-07-21	CI
Nordic Shares Moved Upward Wednesday; Storskogen Group Series B Climbed Highest	23-07-12	DJ
BioGaia's probiotic Protectis increases SARS-CoV-2 antibody response in adults	23-07-05	CI
BioGaia AB Approves Election of Barbro Fridén, Outi Armstrong and Vesa Koskinen as Board Members	23-05-05	CI
BioGaia AB Approves Dividend for 2022	23-05-05	CI

Chart BioGaia AB

Duration

Period

More charts

Company Profile

Biogaia AB is a Sweden-based healthcare company that is engaged in the development and sell of probiotic products. The Company develops, markets and sells probiotic products with documented health benefits. The products are primarily based on different strains of the lactic acid bacterium Limosilactobacillus reuteri. The Companyâs activities are divided into three segments: The Paediatrics segment drops, gut health tablets, oral rehydration solution (ORS) and cultures to be used as ingredients in licensee products; The Adult Health segment (gut health tablets, oral health lozenges and cultures as an ingredient in a licenseeâs dairy products) and the Other (royalties in respect of development projects, revenue from packaging solutions in the subsidiary CapAble, etc.). The Company operates worldwide.

Sector

Pharmaceuticals

Calendar

2024-07-23 - Q2 2024 Earnings Release

More about the company

Income Statement Evolution

More financial data

Ratings for BioGaia AB

Trading Rating

Investor Rating

ESG Refinitiv

B-

More Ratings

Analysts' Consensus

Sell

Buy

Mean consensus

BUY

Number of Analysts

Last Close Price

130.9 SEK

Average target price

140 SEK

Spread / Average Target

+6.95%

Consensus

EPS Revisions

Estimates Revisions

Annual profits - Rate of surprise

Company calendar

Sector Biopharmaceuticals

	1st Jan change	Capi.
BIOGAIA AB	+29.35%	1.23B
CSL LIMITED	-2.32%	90.45B
SAMSUNG BIOLOGICS CO.,LTD.	+3.68%	41.45B
BIOGEN INC.	-10.90%	33.57B
UCB	+58.05%	25.73B
BIOMARIN PHARMACEUTICAL INC.	-19.56%	14.73B
INCYTE CORPORATION	-9.06%	12.82B
BEIJING WANTAI BIOLOGICAL PHARMACY ENTERPRISE CO., LTD.	-11.34%	11.7B
CHONGQING ZHIFEI BIOLOGICAL PRODUCTS CO., LTD.	-43.53%	11.44B
SWEDISH ORPHAN BIOVITRUM AB	+3.75%	8.79B

Biopharmaceuticals

BioGaia AB

Equities

BIOG B

SE0017769995

Pharmaceuticals

Biogaia AB Provides Earnings Guidance for the Second Quarter of 2022

Latest news about BioGaia AB

Chart BioGaia AB

Company Profile

Income Statement Evolution

Ratings for BioGaia AB

Analysts' Consensus

EPS Revisions

Annual profits - Rate of surprise

Sector Biopharmaceuticals